BioCryst Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US09058V1035

Introdução

Esta página fornece uma análise abrangente do histórico conhecido de negociações internas de Sanj K Patel. Insiders são oficiais, diretores ou investidores significativos em uma empresa. É ilegal para insiders realizarem negociações em suas próprias empresas baseados em informações específicas, não públicas. Isso não significa que seja ilegal para eles realizarem qualquer negociação em suas próprias empresas. No entanto, eles devem reportar todas as negociações à SEC através de um Formulário 4. Apesar dessas restrições, pesquisas acadêmicas sugerem que insiders - em geral - tendem a superar o mercado em suas próprias empresas.

Rentabilidade Média de Negociação

A rentabilidade média de negociação é o retorno médio de todas as compras de mercado abertas feitas pelo insider nos últimos três anos. Para calcular isso, examinamos cada compra de mercado aberto, não planejada, feita pelo insider, excluindo todas as negociações que foram marcadas como parte de um plano de negociação 10b5-1. Em seguida, calculamos o desempenho médio dessas negociações ao longo de 3, 6 e 12 meses, fazendo a média de cada uma dessas durações para gerar uma métrica de desempenho final para cada negociação. Finalmente, fazemos a média de todas as métricas de desempenho para calcular uma métrica de desempenho para o insider. Esta lista inclui apenas insiders que fizeram pelo menos três negociações nos últimos dois anos.

Se a rentabilidade de negociação deste insider é "N/A", então o insider ou não fez quaisquer compras de mercado aberto nos últimos três anos, ou as negociações que eles fizeram são muito recentes para calcular uma métrica de desempenho confiável.

Frequência de Atualização: Diariamente

Veja a lista dos negociantes internos mais rentáveis.

Empresas com Posições Internas Reportadas

As declarações à SEC indicam que Sanj K Patel reportou posses ou negociações nas seguintes empresas:

Ativo Título Últimas Posições Reportadas
US:KNSA / Kiniksa Pharmaceuticals International, plc CHAIRMAN & CEO, Director 951,794
US:SYRS / Syros Pharmaceuticals, Inc. Director 11,000
US:BCRX / BioCryst Pharmaceuticals, Inc. Director 30,000
US:GEVA / Synageva Biopharma Corp President & CEO, Director 0
US:ICPT / Intercept Pharmaceuticals Inc Director 551
Como Interpretar os Gráficos

Os gráficos a seguir mostram o desempenho das ações dos a ativos ubsequentes a cada transação de mercado aberto, não planejada feita por Sanj K Patel. Transações não planejadas são negociações que não foram feitas como parte de um plano de negociação 10b5-1. O desempenho das ações é representado como mudança percentual cumulativa no preço das ações. Por exemplo, se uma transação interna foi feita em 1 de janeiro de 2019, o gráfico mostrará a mudança percentual diária da segurança até o dia presente. Se o preço da ação passasse de $10 para $15 durante este período, a mudança percentual cumulativa no preço das ações seria de 50%. Uma mudança no preço de $10 para $20 seria de 100%, e uma mudança no preço de $10 para $5 seria de -50%.

Ultimamente, estamos tentando determinar quão estreitamente as negociações do interno correlacionam-se a retornos excessivos (positivos ou negativos) no preço da ação para ver se o interno está cronometrando suas transações para lucrar com informações internas. Considere a situação onde um interno estava fazendo isso. Nesta situação, esperaríamos (a) retornos positivos após compras, ou (b) retornos negativos após vendas. No caso de (a), o gráfico de COMPRA mostraria uma série de curvas ascendentes, indicando retornos positivos após cada transação de compra. No caso de (b), o gráfico de VENDA mostraria uma série de curvas descendentes, indicando retornos negativos após cada transação de venda.

No entanto, isso sozinho não é suficiente para tirar conclusões. Se, por exemplo, o preço da ação da empresa estivesse em uma escalada não cíclica ao longo de muitos anos, então esperaríamos que todos os gráficos pós-compra tivessem uma inclinação ascendente. Da mesma forma, declínios não cíclicos ao longo de muitos anos resultariam em gráficos pós-negociação inclinados para baixo. Nenhum desses gráficos sugeriria atividade de negociação interna.

O indicador mais forte seria uma situação em que o preço da ação fosse extremamente cíclico, e houvesse sinais positivos no gráfico de COMPRA e gráficos negativos no gráfico de VENDA. Esta situação seria altamente sugestiva de um interno que estava cronometrando transações para sua vantagem financeira.

Compras Internas BCRX / BioCryst Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em BCRX / BioCryst Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

BCRX / BioCryst Pharmaceuticals, Inc. Insider Trades
Vendas Internas BCRX / BioCryst Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em BCRX / BioCryst Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

BCRX / BioCryst Pharmaceuticals, Inc. Insider Trades
Compras Internas KNSA / Kiniksa Pharmaceuticals International, plc - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em BCRX / BioCryst Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

KNSA / Kiniksa Pharmaceuticals International, plc Insider Trades
Vendas Internas KNSA / Kiniksa Pharmaceuticals International, plc - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em BCRX / BioCryst Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

KNSA / Kiniksa Pharmaceuticals International, plc Insider Trades
Compras Internas SYRS / Syros Pharmaceuticals, Inc. - Análise de Lucro de Curto Prazo

Nesta seção, analisamos a lucratividade de cada compra interna de mercado aberto, não planejada, feita em BCRX / BioCryst Pharmaceuticals, Inc.. Esta análise ajuda a entender se o interno gera consistentemente retornos anormais, e vale a pena seguir. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as compras de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Máx
Preço em
Máx
Lucro
Máx ($)
Retorno Máx (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Vendas Internas SYRS / Syros Pharmaceuticals, Inc. - Análise de Perda de Curto Prazo

Nesta seção, analisamos a evitação de perdas de curto prazo de cada venda interna de mercado aberto, não planejada feita em BCRX / BioCryst Pharmaceuticals, Inc.. Um padrão consistente de evitação de perdas pode sugerir que transações futuras de venda possam prever declínios no preço. Esta análise é para um ano seguinte a cada transação, e os resultados são teóricos.

A tabela a seguir mostra as vendas de mercado aberto mais recentes que não faziam parte de um plano de negociação automático.

Data de Negociação Ticker Insider Ações
Reportadas
Preço
Reportado
Ações
Ajustadas
Preço
Ajustado
Base de Custos Dias para
Mín
Preço em
Mín
Máxima Perda
Evitada ($)
Máxima Perda
Evitada (%)
Não há negociações abertas de mercado não planejadas conhecidas para esta combinação de insider e ativo

O Preço Ajustado é o preço ajustado pela divisão. Ações Ajustadas são as ações ajustadas pela divisão.

SYRS / Syros Pharmaceuticals, Inc. Insider Trades
Histórico de Negociações Insider

Esta tabela mostra a lista completa de negociações insider realizadas por Sanj K Patel conforme divulgadas para a Comissão de Valores Mobiliários (SEC).

Data do Arquivo Data da Transação Formulário Ticker Ativo Código 10b5-1 Ações Ações Restantes Variação
Percentual
Preço
da Ação
Valor
da Transação
Valor
Restante
2026-06-02 2026-06-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
C - Conversion 900,000 951,794 1,737.65
2026-05-01 2026-05-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -48,565 0 -100.00 54.02 -2,623,481
2026-05-01 2026-05-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 48,565 48,565 30.93 1,502,115 1,502,115
2026-04-30 2026-04-30 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -2,141 0 -100.00 54.01 -115,635
2026-04-30 2026-04-30 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 2,141 2,141 30.93 66,221 66,221
2026-04-30 2026-04-29 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -22,544 0 -100.00 54.01 -1,217,601
2026-04-30 2026-04-29 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 22,544 22,544 30.93 697,286 697,286
2026-04-30 2026-04-28 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -51,750 0 -100.00 54.02 -2,795,535
2026-04-30 2026-04-28 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -243,596 51,750 -82.48 52.02 -12,671,864 2,692,035
2026-04-30 2026-04-28 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -113,673 295,346 -27.79 51.47 -5,850,749 15,201,459
2026-04-30 2026-04-28 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -74,635 409,019 -15.43 50.43 -3,763,843 20,626,828
2026-04-30 2026-04-28 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 51,750 483,654 11.98 30.93 1,600,628 14,959,418
2026-04-30 2026-04-28 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 431,904 431,904 10.36 4,474,525 4,474,525
2026-04-08 2026-04-07 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -4,831 76,174 -5.96 48.94 -236,429 3,727,956
2026-04-08 2026-04-07 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 9,991 81,005 14.07
2026-04-08 2026-04-06 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -7,278 0 -100.00 50.01 -363,973
2026-04-08 2026-04-06 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 7,278 7,278 10.36 75,400 75,400
2026-04-03 2026-04-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -10,313 71,014 -12.68 48.13 -496,365 3,417,904
2026-04-03 2026-04-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 21,327 81,327 35.54
2025-11-14 2025-11-13 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
G - Gift 60,000 60,000
2025-11-14 2025-11-13 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
G - Gift -60,000 51,794 -53.67
2025-11-14 2025-11-12 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
G - Gift 111,794 111,794
2025-11-14 2025-11-12 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
G - Gift -111,794 0 -100.00
2025-10-22 2025-10-22 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -97,390 111,794 -46.56 38.83 -3,781,654 4,340,961
2025-10-22 2025-10-22 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 97,390 209,184 87.12 3.80 370,082 794,899
2025-10-22 2025-10-21 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -39,331 111,794 -26.03 38.77 -1,524,863 4,334,253
2025-10-22 2025-10-21 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 39,331 151,125 35.18 3.80 149,458 574,275
2025-10-22 2025-10-20 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -22,314 111,794 -16.64 39.32 -877,386 4,395,740
2025-10-22 2025-10-20 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -98,934 134,108 -42.45 38.81 -3,839,629 5,204,731
2025-10-22 2025-10-20 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 121,248 233,042 108.46 3.80 460,742 885,560
2025-09-03 2025-09-02 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -3,177 111,794 -2.76 34.28 -108,908 3,832,298
2025-09-03 2025-09-02 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 6,569 114,971 6.06
2025-09-03 2025-09-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -10,983 108,402 -9.20 33.49 -367,821 3,630,383
2025-09-03 2025-09-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 9,992 119,385 9.13
2025-09-03 2025-09-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 6,481 109,393 6.30
2025-09-03 2025-09-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 6,238 102,912 6.45
2025-05-28 2025-05-28 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -62,116 96,674 -39.12 27.33 -1,697,630 2,642,100
2025-05-28 2025-05-28 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 62,116 158,790 64.25 1.59 98,764 252,476
2025-05-28 2025-05-27 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -19,317 96,674 -16.65 27.01 -521,752 2,611,165
2025-05-28 2025-05-27 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 19,317 115,991 19.98 1.59 30,714 184,426
2025-05-28 2025-05-23 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -4,837 96,674 -4.77 27.00 -130,599 2,610,198
2025-05-28 2025-05-23 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 4,837 101,511 5.00 1.59 7,691 161,402
2025-05-22 2025-05-20 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -2,349 96,674 -2.37 27.02 -63,470 2,612,131
2025-05-22 2025-05-20 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 2,349 99,023 2.43 1.59 3,735 157,447
2025-05-15 2025-05-13 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -2,872 96,674 -2.89 27.03 -77,630 2,613,098
2025-05-15 2025-05-13 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 2,872 99,546 2.97 1.59 4,566 158,278
2025-05-09 2025-05-09 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -6,029 96,674 -5.87 27.05 -163,084 2,615,032
2025-05-09 2025-05-09 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 6,029 102,703 6.24 1.59 9,586 163,298
2025-05-09 2025-05-08 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -101 96,674 -0.10 27.00 -2,727 2,610,198
2025-05-09 2025-05-08 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 101 96,775 0.10 1.59 161 153,872
2025-05-09 2025-05-07 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -1,965 96,674 -1.99 27.00 -53,055 2,610,198
2025-05-09 2025-05-07 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 1,965 98,639 2.03 1.59 3,124 156,836
2025-04-09 2025-04-07 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -4,832 96,674 -4.76 20.28 -97,993 1,960,549
2025-04-09 2025-04-07 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 9,992 101,506 10.92
2025-04-03 2025-04-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -3,017 91,514 -3.19 21.77 -65,680 1,992,260
2025-04-03 2025-04-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -2,304 94,531 -2.38 21.77 -50,158 2,057,940
2025-04-03 2025-04-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 6,238 96,835 6.89
2025-04-03 2025-04-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 6,481 90,597 7.70
2025-03-19 2025-03-16 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -2,004 84,116 -2.33 22.61 -45,310 1,901,863
2025-03-19 2025-03-16 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 6,569 86,120 8.26
2024-11-08 2024-11-06 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -89,561 79,551 -52.96 23.00 -2,059,903 1,829,673
2024-11-08 2024-11-06 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise X 89,561 169,112 112.58 1.59 142,402 268,888
2024-09-04 2024-09-02 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -3,177 79,551 -3.84 26.74 -84,953 2,127,194
2024-09-04 2024-09-02 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 6,569 82,728 8.63
2024-09-04 2024-09-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
F - Taxes -7,967 76,159 -9.47 26.74 -213,038 2,036,492
2024-09-04 2024-09-01 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 16,474 84,126 24.35
2024-07-25 2024-07-23 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -63,049 63,012 -50.01 27.01 -1,702,953 1,701,954
2024-07-25 2024-07-23 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -50,000 126,061 -28.40 25.05 -1,252,500 3,157,828
2024-07-25 2024-07-23 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
S - Sale X -23,075 176,061 -11.59 23.25 -536,494 4,093,418
2024-07-25 2024-07-23 4 KNSA Kiniksa Pharmaceuticals International, plc
Class A Ordinary Share
M - Exercise 136,124 199,136 216.03 1.59 216,437 316,626
2024-04-08 2024-04-08 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -4,075 63,012 -6.07 17.90 -72,942 1,127,915
2024-04-08 2024-04-08 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 9,992 67,087 17.50
2024-04-03 2024-04-01 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -1,903 57,095 -3.23 19.70 -37,489 1,124,772
2024-04-03 2024-04-01 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 6,482 58,998 12.34
2024-03-11 2024-03-07 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
S - Sale X -65,012 0 -100.00 21.02 -1,366,552
2024-03-06 2024-03-06 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
S - Sale X -5,582 65,012 -7.91 21.00 -117,222 1,365,252
2024-03-06 2024-03-04 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
S - Sale X -3,336 70,594 -4.51 22.00 -73,392 1,553,068
2024-03-06 2024-03-04 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
S - Sale X -9,406 73,930 -11.29 21.31 -200,442 1,575,448
2023-09-06 2023-09-02 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -2,187 52,516 -4.00 17.76 -38,841 932,684
2023-09-06 2023-09-02 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 6,569 54,703 13.65
2023-09-06 2023-09-01 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -4,432 48,134 -8.43 17.76 -78,712 854,860
2023-09-06 2023-09-01 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 9,992 52,566 23.47
2023-04-11 2023-04-10 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -2,933 42,574 -6.45 10.71 -31,412 455,968
2023-04-11 2023-04-10 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 9,992 45,507 28.13
2023-03-20 2023-03-20 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -3,523 35,515 -9.02 11.12 -39,176 394,927
2023-03-20 2023-03-20 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 12,002 39,038 44.39
2023-03-20 2023-03-16 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -1,929 27,036 -6.66 11.46 -22,106 309,833
2023-03-20 2023-03-16 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 6,569 28,965 29.33
2022-09-06 2022-09-02 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -1,929 22,396 -7.93 11.44 -22,068 256,210
2022-09-06 2022-09-02 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 6,569 24,325 37.00
2022-04-11 2022-04-07 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Restricted Share Unit
A - Award 39,967 39,967
2022-04-11 2022-04-07 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
A - Award 239,795 239,795
2022-03-23 2022-03-21 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Restricted Share Unit
M - Exercise -18,555 0 -100.00
2022-03-23 2022-03-21 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -5,446 17,756 -23.47 10.98 -59,797 194,961
2022-03-23 2022-03-21 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 18,555 23,202 399.29
2022-03-18 2022-03-16 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Restricted Share Unit
M - Exercise -6,569 19,707 -25.00
2022-03-18 2022-03-16 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
F - Taxes -1,922 4,647 -29.26 10.13 -19,470 47,074
2022-03-18 2022-03-16 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Share
M - Exercise 6,569 6,569
2021-09-07 2021-09-02 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Restricted Share Units
A - Award 26,276 26,276
2021-09-07 2021-09-02 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
A - Award 157,658 157,658
2021-03-23 2021-03-20 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Restricted Share Units
A - Award 12,002 12,002
2021-03-23 2021-03-20 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Restricted Share Units
A - Award 18,555 18,555
2021-03-18 2021-03-16 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Restricted Share Units
A - Award 26,276 26,276
2021-03-18 2021-03-16 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
A - Award 157,658 157,658
2021-02-10 2021-02-10 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
M - Exercise X -1,600 325,271 -0.49
2021-02-10 2021-02-10 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -1,137 83,336 -1.35 23.07 -26,231 1,922,562
2021-02-10 2021-02-10 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -1,600 0 -100.00 23.06 -36,896
2021-02-10 2021-02-10 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
M - Exercise X 1,600 1,600 1.59 2,544 2,544
2021-02-10 2021-02-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
M - Exercise X -20,401 326,871 -5.87
2021-02-10 2021-02-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -23,569 84,473 -21.81 23.08 -543,973 1,949,637
2021-02-10 2021-02-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -20,401 0 -100.00 23.04 -470,039
2021-02-10 2021-02-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
M - Exercise X 20,401 20,401 1.59 32,438 32,438
2021-02-10 2021-02-08 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
M - Exercise X -4,924 347,272 -1.40
2021-02-10 2021-02-08 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -4,528 108,042 -4.02 23.00 -104,144 2,484,966
2021-02-10 2021-02-08 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -4,924 0 -100.00 23.00 -113,252
2021-02-10 2021-02-08 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
M - Exercise X 4,924 4,924 1.59 7,829 7,829
2020-10-14 2020-10-12 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
M - Exercise X -150,700 352,196 -29.97
2020-10-14 2020-10-12 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -99,330 112,570 -46.88 21.02 -2,087,917 2,366,221
2020-10-14 2020-10-12 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -150,700 0 -100.00 21.02 -3,167,714
2020-10-14 2020-10-12 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
M - Exercise X 150,700 150,700 1.59 239,613 239,613
2020-10-14 2020-10-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
M - Exercise X -872 502,896 -0.17
2020-10-14 2020-10-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -670 211,900 -0.32 21.00 -14,070 4,449,900
2020-10-14 2020-10-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -872 0 -100.00 21.00 -18,312
2020-10-14 2020-10-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
M - Exercise X 872 872 1.59 1,386 1,386
2020-09-14 2020-09-10 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
A - Award 180,000 180,000
2020-03-17 2020-03-13 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
A - Award 180,000 180,000
2020-03-10 2020-03-06 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
S - Sale X -33,115 212,570 -13.48 20.00 -662,300 4,251,400
2020-02-13 2019-08-07 5 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
G - Gift 245,685 245,685
2020-02-13 2019-08-07 5 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
G - Gift -245,685 0 -100.00
2020-02-13 2019-07-31 5 KNSA Kiniksa Pharmaceuticals, Ltd.
Class B Common Shares
G - Gift 1,526,160 1,526,160
2020-02-13 2019-07-31 5 KNSA Kiniksa Pharmaceuticals, Ltd.
Class B Common Shares
G - Gift -1,526,160 0 -100.00
2019-09-19 2019-09-17 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
A - Award 190,000 190,000
2019-03-06 2019-03-04 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
A - Award 187,000 187,000
2018-09-24 2018-09-20 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Share Option
A - Award 125,000 125,000
2018-05-29 2018-05-29 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class B Common Shares
C - Conversion 428,203 1,526,160 39.00
2018-05-29 2018-05-29 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Series C Preferred Shares
C - Conversion -63,922 0 -100.00
2018-05-29 2018-05-29 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Series B Preferred Shares
C - Conversion -71,967 0 -100.00
2018-05-29 2018-05-29 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Series A Preferred Shares
C - Conversion -428,203 0 -100.00
2018-05-29 2018-05-29 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
C - Conversion 135,889 245,685 123.76
2018-05-29 2018-02-09 4 KNSA Kiniksa Pharmaceuticals, Ltd.
Series C Preferred Shares
P - Purchase 63,922 63,922 15.64 999,983 999,983
2018-05-23 3 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
329,387
2018-05-23 3 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
329,386
2018-05-23 3 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
329,387
2018-05-23 3 KNSA Kiniksa Pharmaceuticals, Ltd.
Class A Common Shares
329,386
2017-09-22 2017-06-08 4/A SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 11,000 11,000
2017-06-12 2017-06-08 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 11,000 11,000
2017-05-25 2017-05-24 4 BCRX BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant
A - Award 30,000 30,000
2016-09-19 2016-09-15 4 SYRS Syros Pharmaceuticals, Inc.
Stock Option (right to buy)
A - Award 22,000 22,000
2016-05-25 2016-05-23 4 BCRX BIOCRYST PHARMACEUTICALS INC
Automatic Stock Option Grant
A - Award 30,000 30,000
2015-09-29 2015-09-25 4 BCRX BIOCRYST PHARMACEUTICALS INC
Non-Qualified Stock Option
A - Award 16,667 16,667
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -120,000 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -148,000 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -128,000 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -136,052 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Options (Right to Buy)
D - Sale to Issuer -22,512 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
D - Sale to Issuer -72,000 0 -100.00
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
D - Sale to Issuer -1,031 72,000 -1.41
2015-06-23 2015-06-22 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
D - Sale to Issuer -286 0 -100.00
2015-06-09 2015-06-05 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
A - Award 72,000 73,031 6,983.51
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -31,448 136,052 -18.77
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -5,016 0 -100.00
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -13,536 22,512 -37.55
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -26,960 1,031 -96.32 90.06 -2,428,018 92,852
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -4,488 27,991 -13.82 87.26 -391,623 2,442,495
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -13,536 32,479 -29.42 87.55 -1,185,077 2,843,536
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -5,016 46,015 -9.83 87.25 -437,646 4,014,809
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 31,448 51,031 160.59 23.00 723,304 1,173,713
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 5,016 19,583 34.43 3.52 17,656 68,932
2014-12-19 2014-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 13,536 14,567 1,312.90 1.70 23,011 24,764
2014-07-21 2014-07-17 4 ICPT INTERCEPT PHARMACEUTICALS INC
Option to Purchase Common Stock
A - Award 551 551
2014-07-21 2014-07-17 4 ICPT INTERCEPT PHARMACEUTICALS INC
Common Stock
A - Award 452 452
2014-06-05 2014-06-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 120,000 120,000
2014-01-30 2014-01-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -50,971 5,016 -91.04
2014-01-30 2014-01-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -400 1,031 -27.95 91.58 -36,632 94,419
2014-01-30 2014-01-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -1,502 1,431 -51.21 90.85 -136,457 130,006
2014-01-30 2014-01-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -5,600 2,933 -65.63 89.27 -499,912 261,829
2014-01-30 2014-01-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -18,652 8,533 -68.61 88.31 -1,647,158 753,549
2014-01-30 2014-01-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -24,817 27,185 -47.72 87.19 -2,163,794 2,370,260
2014-01-30 2014-01-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 50,971 52,002 4,943.84 3.52 179,418 183,047
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -20,391 36,048 -36.13
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -6,106 0 -100.00
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -24,832 55,987 -30.73
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -812 1,031 -44.06 90.10 -73,161 92,893
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -8,402 1,843 -82.01 88.95 -747,358 163,935
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -32,609 10,245 -76.09 88.38 -2,881,983 905,453
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -9,506 42,854 -18.16 87.16 -828,543 3,735,155
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 20,391 52,360 63.78 1.70 34,665 89,012
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 24,832 31,969 347.93 3.52 87,409 112,531
2014-01-30 2014-01-28 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 6,106 7,137 592.24 0.95 5,801 6,780
2013-07-29 2013-07-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -15,895 80,819 -16.44
2013-07-29 2013-07-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -15,895 1,031 -93.91 47.39 -753,264 48,859
2013-07-29 2013-07-29 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 15,895 16,926 1,541.71 3.52 55,950 59,580
2013-07-29 2013-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -16,882 56,439 -23.02
2013-07-29 2013-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -35,308 96,714 -26.74
2013-07-29 2013-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -17,204 1,031 -94.35 48.31 -831,125 49,808
2013-07-29 2013-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -52,190 18,235 -74.11 47.91 -2,500,423 873,639
2013-07-29 2013-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 16,882 70,425 31.53 1.70 28,699 119,722
2013-07-29 2013-07-26 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 35,308 53,543 193.63 3.52 124,284 188,471
2013-07-29 2013-07-25 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -20,000 73,321 -21.43
2013-07-29 2013-07-25 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -3,664 6,106 -37.50
2013-07-29 2013-07-25 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -8,251 0 -100.00
2013-07-29 2013-07-25 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -14,711 18,235 -44.65 48.73 -716,867 888,592
2013-07-29 2013-07-25 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 20,000 32,946 154.49 1.70 34,000 56,008
2013-07-29 2013-07-25 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 3,664 12,946 39.47 0.95 3,481 12,299
2013-07-29 2013-07-25 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 8,251 9,282 800.29 0.95 7,838 8,818
2013-06-13 2013-06-12 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -14,731 93,321 -13.63
2013-06-13 2013-06-12 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -25,621 9,770 -72.39
2013-06-13 2013-06-12 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -40,352 1,031 -97.51 40.48 -1,633,449 41,735
2013-06-13 2013-06-12 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 14,731 41,383 55.27 1.70 25,043 70,351
2013-06-13 2013-06-12 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 25,621 26,652 2,485.06 0.95 24,340 25,319
2013-06-13 2013-06-11 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -6,105 35,391 -14.71
2013-06-13 2013-06-11 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -23,543 8,251 -74.05
2013-06-13 2013-06-11 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -29,648 1,031 -96.64 40.89 -1,212,307 42,158
2013-06-13 2013-06-11 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 6,105 30,679 24.84 0.95 5,800 29,145
2013-06-13 2013-06-11 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 23,543 24,574 2,283.51 0.95 22,366 23,345
2013-06-10 2013-06-06 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 128,000 128,000
2013-04-09 2013-04-08 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -21,695 41,496 -34.33
2013-04-09 2013-04-08 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -21,695 1,031 -95.46 49.49 -1,073,686 51,024
2013-04-09 2013-04-08 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 21,695 22,726 2,104.27 0.95 20,610 21,590
2013-04-09 2013-04-05 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -9,910 63,191 -13.56
2013-04-09 2013-04-05 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -9,910 1,031 -90.58 50.11 -496,590 51,663
2013-04-09 2013-04-05 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 9,910 10,941 961.20 0.95 9,414 10,394
2013-04-05 2013-04-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -21,931 73,101 -23.08
2013-04-05 2013-04-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -1,200 1,031 -53.79 51.64 -61,968 53,241
2013-04-05 2013-04-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -2,151 2,231 -49.09 50.72 -109,099 113,156
2013-04-05 2013-04-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -18,580 4,382 -80.92 50.12 -931,248 219,630
2013-04-05 2013-04-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 21,931 22,962 2,127.16 0.95 20,834 21,814
2013-04-05 2013-04-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -7,000 95,032 -6.86
2013-04-05 2013-04-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -9,464 31,794 -22.94
2013-04-05 2013-04-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -400 1,031 -27.95 54.44 -21,777 56,131
2013-04-05 2013-04-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -1,500 1,431 -51.18 53.37 -80,060 76,377
2013-04-05 2013-04-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -4,358 2,931 -59.79 52.55 -229,017 154,027
2013-04-05 2013-04-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -10,206 7,289 -58.34 51.08 -521,374 372,359
2013-04-05 2013-04-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 7,000 17,495 66.70 0.95 6,650 16,620
2013-04-05 2013-04-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 9,464 10,495 917.94 0.95 8,991 9,970
2013-02-22 2013-02-21 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -45,392 41,258 -52.39
2013-02-22 2013-02-21 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -45,392 1,031 -97.78 49.02 -2,225,116 50,540
2013-02-22 2013-02-21 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 45,392 46,423 4,402.72 0.95 43,122 44,102
2013-02-22 2013-02-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -5,954 102,032 -5.51
2013-02-22 2013-02-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise -18,654 86,650 -17.71
2013-02-22 2013-02-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -5,954 1,031 -85.24 49.60 -295,318 51,138
2013-02-22 2013-02-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -18,654 6,985 -72.76 49.49 -923,186 345,688
2013-02-22 2013-02-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 5,954 25,639 30.25 0.95 5,656 24,357
2013-02-22 2013-02-20 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 18,654 19,685 1,809.31 0.95 17,721 18,701
2012-12-17 2012-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -32,319 105,304 -23.48
2012-12-17 2012-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -1,600 1,031 -60.81 47.53 -76,048 49,003
2012-12-17 2012-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -23,715 2,631 -90.01 47.03 -1,115,316 123,736
2012-12-17 2012-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -7,004 26,346 -21.00 45.97 -321,974 1,211,126
2012-12-17 2012-12-17 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 32,319 33,350 3,134.72 0.95 30,703 31,682
2012-12-17 2012-12-14 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -13,281 137,623 -8.80
2012-12-17 2012-12-14 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -13,281 1,031 -92.80 45.30 -601,629 46,704
2012-12-17 2012-12-14 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 13,281 14,312 1,288.17 0.95 12,617 13,596
2012-12-17 2012-12-13 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -14,400 150,904 -8.71
2012-12-17 2012-12-13 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -2,701 1,031 -72.37 47.07 -127,136 48,529
2012-12-17 2012-12-13 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -3,300 3,732 -46.93 45.87 -151,371 171,187
2012-12-17 2012-12-13 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -8,399 7,032 -54.43 45.12 -378,963 317,284
2012-12-17 2012-12-13 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 14,400 15,431 1,396.70 0.95 13,680 14,659
2012-12-06 2012-12-05 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -12,000 165,304 -6.77
2012-12-06 2012-12-05 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -12,000 1,031 -92.09 48.10 -577,255 49,596
2012-12-06 2012-12-05 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 12,000 13,031 1,163.92 0.95 11,400 12,379
2012-12-06 2012-12-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -23,000 177,304 -11.48
2012-12-06 2012-12-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -23,000 1,031 -95.71 49.34 -1,134,850 50,871
2012-12-06 2012-12-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 23,000 24,031 2,230.84 0.95 21,850 22,829
2012-12-04 2012-12-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -30,000 200,304 -13.03
2012-12-04 2012-12-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -30,000 1,031 -96.68 49.42 -1,482,492 50,948
2012-12-04 2012-12-03 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 30,000 31,031 2,909.80 0.95 28,500 29,479
2012-12-04 2012-11-30 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -5,000 230,304 -2.12
2012-12-04 2012-11-30 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -5,000 1,031 -82.90 48.87 -244,326 50,380
2012-12-04 2012-11-30 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 5,000 6,031 484.97 0.95 4,750 5,729
2012-09-05 2012-09-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -54,813 235,304 -18.89
2012-09-05 2012-09-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -54,813 1,031 -98.15 49.36 -2,705,372 50,886
2012-09-05 2012-09-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 54,813 55,844 5,316.49 0.95 52,072 53,052
2012-09-05 2012-08-31 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise X -15,187 290,117 -4.97
2012-09-05 2012-08-31 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -15,187 1,031 -93.64 49.88 -757,518 51,426
2012-09-05 2012-08-31 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 15,187 16,218 1,473.04 0.95 14,428 15,407
2012-06-29 2012-06-27 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
A - Award 148,000 148,000
2012-06-05 2012-06-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise -20,866 305,304 -6.40
2012-06-05 2012-06-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -20,866 1,031 -95.29 34.69 -723,785 35,763
2012-06-05 2012-06-04 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 20,866 21,897 2,023.86 0.95 19,823 20,802
2012-06-05 2012-06-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise -9,234 107,986 -7.88
2012-06-05 2012-06-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise -19,900 326,170 -5.75
2012-06-05 2012-06-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -9,234 1,031 -89.96 35.96 -332,087 37,078
2012-06-05 2012-06-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -19,900 10,265 -65.97 35.70 -710,446 366,469
2012-06-05 2012-06-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 9,234 30,165 44.12 0.95 8,772 28,657
2012-06-05 2012-06-01 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 19,900 20,931 1,930.16 0.95 18,905 19,884
2012-03-27 2012-03-23 4 GEVA SYNAGEVA BIOPHARMA CORP
Stock Option (Right to Buy)
M - Exercise -50,000 346,070 -12.62
2012-03-27 2012-03-23 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
S - Sale X -50,000 1,031 -97.98 33.53 -1,676,410 34,568
2012-03-27 2012-03-23 4 GEVA SYNAGEVA BIOPHARMA CORP
Common Stock
M - Exercise X 50,000 51,031 4,849.66 0.95 47,500 48,479
P
Compra de mercado aberto ou privada de ativo não-derivativo ou derivativo
S
Venda de mercado aberto ou privada de ativo não-derivativo ou derivativo
A
Concessão, premiação, ou outra aquisição de ativos da empresa (como uma opção)
C
Conversão de derivativo
D
Venda ou transferência de ativos de volta para a empresa
F
Pagamento do preço de exercício ou responsabilidade fiscal utilizando parte dos ativos recebidos da empresa
G
Doação de ativos pelo ou para o insider
K
Swaps de capital e transações de hedge similares
M
Exercício ou conversão de ativo derivativo recebido da empresa (como uma opção)
V
Uma transação voluntariamente reportada no Formulário 4
J
Outro (acompanhado de uma nota explicativa descrevendo a transação)